Human Multiple Myeloma Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated)

Description

Human Multiple Myeloma Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated) are derived from the peripheral blood of newly diagnosed and untreated multiple myeloma patients. They are separated by gradient centrifugation technology (such as Ficoll density gradient method) to obtain a mixed cell population rich in lymphocytes (T/B cells, NK cells), monocytes and dendritic cells. Morphologically, the cells are round and mononuclear, grow in suspension, and have weak adhesion ability. Clonal B cells overexpress monoclonal immunoglobulins; increased myeloid-derived suppressor cells (MDSCs) markers; T cells show inhibited function via arginase 1 and IDO pathways.Functionally, they contain immune surveillance and regulatory components, but they are abnormal due to the disease state: B cells proliferate clonally and secrete monoclonal immunoglobulins, the proportion of myeloid-derived suppressor cells (MDSCs) increases, and T cell function is inhibited through pathways such as arginase 1 and IDO, promoting tumor immune escape.